Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEO Of Dainippon Sumitomo Of Japan Justifies U.S.-Based Sepracor Buy

This article was originally published in PharmAsia News

Executive Summary

Japan's Dainippon Sumitomo Pharma may have made a risky deal in buying U.S. drug maker Sepracor, according to some, but CEO Masayo Tada said at a news conference the company has many financing options. Tada denied suggestions the $2.6 billion purchase price of Sepracor was excessive, saying Dainippon Sumitomo was financially healthy enough to manage the deal. The company was motivated to make the acquisition because of dwindling sales many drug makers are facing in Japan. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel